

5' Nucleotidase - Pipeline Review, H2 2019

<https://marketpublishers.com/r/59CD82B84F06EN.html>

Date: August 2019

Pages: 87

Price: US\$ 3,500.00 (Single User License)

ID: 59CD82B84F06EN

Abstracts

5' Nucleotidase - Pipeline Review, H2 2019

SUMMARY

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5'-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides.

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 11 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Ovarian Cancer, Solid Tumor, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Metastatic Breast Cancer, Bladder Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Kidney Cancer (Renal Cell Cancer), Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Pancreatic Cancer, Muscle Invasive Bladder Cancer (MIBC), Non-Small Cell Lung Carcinoma, Renal Cell Carcinoma, Sarcomas, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.

The latest report 5' Nucleotidase - Pipeline Review, H2 2019, outlays comprehensive

information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)

The report reviews 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects

The report assesses 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Overview

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Companies

Involved in Therapeutics Development

Arcus Biosciences Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Corvus Pharmaceuticals Inc

Evotec SE

I-Mab Biopharma Co Ltd

Innate Pharma SA

InteRNA Technologies BV

Merck & Co Inc

Novartis AG

ORIC Pharmaceuticals Inc

Phanes Therapeutics Inc

Selvita SA

Shanghai Henlius Biotech Inc

Xcella Biosciences Inc

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drug Profiles

AB-680 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Inhibit CD73 for Non-Small Cell Lung Cancer and Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody1 to Inhibit CD73 for Non-Small Cell Lung Cancer and Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986179 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-708 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPI-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DN-018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab + oleclumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HLX-23 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-1B3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPH-5301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit CD73 for Non Small Cell Lung Cancer and Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit CD73 for Non Small Cell Lung Cancer and Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NZV-930 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oleclumab - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
PT-199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ADORA2A and CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ADORA2A and CD73 for Oncology 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJ-4309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

TJL-1D5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Dormant Products

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Product Development Milestones

Featured News & Press Releases

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Arcus Biosciences Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Calithera Biosciences Inc, H2 2019
Pipeline by Corvus Pharmaceuticals Inc, H2 2019
Pipeline by Evotec SE, H2 2019
Pipeline by I-Mab Biopharma Co Ltd, H2 2019
Pipeline by Innate Pharma SA, H2 2019
Pipeline by InteRNA Technologies BV, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by ORIC Pharmaceuticals Inc, H2 2019
Pipeline by Phanes Therapeutics Inc, H2 2019
Pipeline by Selvita SA, H2 2019
Pipeline by Shanghai Henlius Biotech Inc, H2 2019
Pipeline by Xcella Biosciences Inc, H2 2019
Dormant Projects, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Arcus Biosciences Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Corvus Pharmaceuticals Inc

Evotec SE

I-Mab Biopharma Co Ltd

Innate Pharma SA

InteRNA Technologies BV

Merck & Co Inc

Novartis AG

ORIC Pharmaceuticals Inc

Phanes Therapeutics Inc

Selvita SA

Shanghai Henlius Biotech Inc

Xcella Biosciences Inc

I would like to order

Product name: 5' Nucleotidase - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/59CD82B84F06EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/59CD82B84F06EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970